Compares two antibiotic approaches for lung flare-ups in children with cystic fibrosis
Compares two antibiotic plans for lung flare-ups in children with cystic fibrosis.
Plain-language title generated from the registry record
Registry title: Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
Key facts
- Where
- Toronto and Vancouver, CanadaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 18 years old?
Source: NCT06654752, who can take part
Where in Canada
- The Hospital for Sick Children & Toronto Canada CF Centre PediatricsToronto, CanadaTaking people
- British Columbia Children's HospitalVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Washington, the Collaborative Health Studies Coordinating Center
- Trial code
- NCT06654752
- Record updated
- 9 November 2026
- Original description
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.Read full original descriptionShow less
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Randomized Controlled Trial (STOP PEDS RCT)
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Inclusion: Age; For main cohort and non-HEMT cohort: age 6 to <19 years; For preschool cohort: age 3 to <6 years; Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:; sweat chloride ≥ 60 mEq/liter; two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene; Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study; Highly Effective Modulator Therapy; For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment; For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months; For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry; For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations; Ability to receive text messages and access the internet.
Exclusion: Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report; Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report; History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment; Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment; Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment; Treatment with chronic oral antibiotics other than azithromycin at enrollment; Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment; Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data; History of solid organ transplant.